During the corresponding time, Renovorx Inc recorded a revenue increase by 115.4 % year on year, sequentially revenue grew by 61.46 %. While revenue at the Renovorx Inc 's corporate clients
In an important development for cancer treatment, RenovoRx, Inc. (Nasdaq: RNXT) a pioneering life sciences firm announced the upcoming presentation of groundbreaking pre-clinical data at the Society of Surgical Oncology (SSO) 2025 ...
In a positive development for RenovoRx Inc. the company has announced a significant increase in the production of its FDA-cleared RenovoCath delivery system. This decision comes in response to heightened demand from physicians in both oncology and interventional radiology. The expansion signals an optimistic outlook for the company s position in the medical device market and reflects growing confidence from healthcare practitioners in its innovative technology.RenovoRx s partnership with Medical Murray, a key manufacturing partner, is set to deepen as the company seeks to scale up production capabilities. This collaboration is crucial not only for ensuring the quality and reliability of the RenovoCath system...
RenovoRx, an emerging pioneer in the realm of targeted cancer therapies, has recently announced a significant milestone: their latest data on the use of the RenovoCath™ system and targeted therapy platform for the treatment of Locally Advanced Pancreatic Cancer (LAPC) has been accepted for publication in The Oncologist, a renowned international peer-reviewed journal. This pivotal publication is anticipated to be featured in the Summer 2024 issue of The Oncologist, marking a monumental stride for RenovoRx and the field of oncologic treatment. Facts and Details: 1. Announcement and Anticipation : RenovoRx disclosed that their upcoming data on targeted therapy for LAPC will be published in the esteemed journ...
RenovoRx CEO Updates Shareholders on Significant Q1 Milestones LOS ALTOS, Calif. - RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company specializing in the development of novel precision oncology therapies, has recently seen substantial advancements in Q1 of 2024. Chief Executive Officer, Shaun Bagai, issued an update letter to shareholders to highlight these key achievements and outline the company s strategic directions for the near future.In the letter, Bagai acknowledged the pivotal nature of the first quarter for RenovoRx. The company has made significant strides in developing its proprietary local drug-delivery platform, which is the core of its precision oncology therapies. This...
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024RenovoRx, a prominent biopharmaceutical company known for its groundbreaking precision oncology therapies, has announced that its Chief Executive Officer, Shaun R. Bagai, will be presenting at the highly anticipated Aegis Capital Virtual Conference. The conference is scheduled to take place on May 7-9, 2024, and will bring together industry leaders, investors, and stakeholders from across the globe.RenovoRx has been at the forefront of developing innovative drug-delivery platforms for the treatment of cancer. With a strong focus on precision medicine, the company aims to revolutionize the way oncology therapies are d...
Sources:
Renovorx Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Renovorx Inc’s corporate clients.
For your research, we’ve provided 9 tables on Renovorx Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
161.94 %